SCHEMBL2211769

SCHEMBL2211769

Clc1ccc(CN2CCC(NCCCCOc3ccc(-c4csc(N(c5ccccc5)c5ccccc5)n4)cc3)CC2)cc1Cl

nearest known ligand 0.45

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
UTS2R Q9UKP6 2/20 0.44
MAOB P27338 4/20 0.44
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
CCR3 P51677 5/20 0.43
HRH1 P35367 3/20 0.43
BCHE P06276 1/20 0.41
ACHE P22303 1/20 0.41
SIGMAR1 Q99720 1/20 0.40
CCR1 P32246 2/20 0.39
ATP4A P20648 1/20 0.39
ATP4B P51164 1/20 0.39
DRD2 P14416 1/20 0.39
DRD4 P21917 1/20 0.39
HTR2A P28223 1/20 0.39
MCHR1 Q99705 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2211760 0.87 SIGMAR1 (0.51) UTS2RMEN1KMT2ACCR3SIGMAR1
Trifluoroacetic Acid SCHEMBL2210369 0.85 UTS2R (0.47) UTS2RMAOBMEN1KMT2ACCR3
Trifluoroacetic Acid SCHEMBL2213449 0.83 UTS2R (0.47) UTS2RMAOBMEN1KMT2ABCHE
SCHEMBL2213989 0.81 UTS2R (0.46) UTS2RMAOBMEN1KMT2ACCR3
Trifluoroacetic Acid SCHEMBL2208294 0.79 UTS2R (0.44) UTS2RMAOBMEN1KMT2ACCR3
Trifluoroacetic Acid SCHEMBL2213098 0.78 UTS2R (0.44) UTS2RMAOBMEN1KMT2ACCR3
Trifluoroacetic Acid SCHEMBL6108505 0.78 UTS2R (0.44) UTS2RMAOBMEN1KMT2ACCR3
Trifluoroacetic Acid SCHEMBL2214532 0.78 AR (0.46) UTS2RMAOBMEN1KMT2ACCR3
Trifluoroacetic Acid SCHEMBL2209929 0.77 MEN1 (0.41) UTS2RMAOBMEN1KMT2ACCR3
Trifluoroacetic Acid SCHEMBL2212565 0.77 UTS2R (0.44) UTS2RMAOBMEN1KMT2ACCR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1389616-B1 3,4-Dihalobenzylpiperidine derivatives and their medical use MITSUBISHI TANABE PHARMA CORP (JP) 2011-07-27 EP disclosed
US-7115635-B2 Benzylpiperidine compound MITSUBISHI PHARMA CORPORATION (JP) 2006-10-03 US disclosed
US-20040158071-A1 Chemokine inhibitors and stability in blood MITSUBISHI PHARMA CORPORATION (JP) 2004-08-12 US disclosed
EP-1389616-A1 NOVEL BENZYLPIPERIDINE COMPOUND Mitsubishi Pharma Corporation (JP) 2004-02-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040158071-A1 Chemokine inhibitors and stability in blood CCL2, CXCR1, CCR5 UTS2R 2154/4885MAOB 2634/4885MEN1 3525/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.